Clinical evidence: The SURMOUNT-1 trial, published in the New England Journal of Medicine , showed that participants on the highest dose of tirzepatide (15 mg) lost an average of 22.5 percent of their body weight over 72 weeks the most weight loss ever demonstrated by a pharmaceutical agent in a clinical trial (Jastreboff et al., 2022)
The selected cases include Cinque Terre in Italy (over-tourism), Honghe Hani Rice Terraces in China (unconscious use and destruction of natural formations), Lamu Island in Kenya (unpreparedness against tourism growth), Lenggong Valley in Malaysia (archaeological site destruction), Wachau Valley in Austria (increasing destruction of natural and cultural landscapes), Bagan in Myanmar (historic temples and uncontrolled tourism), Lake Bled in Slovenia (environmental carrying capacity issues), Giethoorn in the Netherlands (water canals and car-free living affected by tourism), Matka Canyon in North Macedonia (tourism integration challenges), and La Picadora in Spain (local over-reliance on tourism for economic gain)
Results Driven
CJC-1295 No DAC and Ipamorelin are combined into one formulation, delivering complementary research properties in a single blend
Use of medications that affect blood sugar (insulin, GLP-1s, steroids)
